<DOC>
	<DOCNO>NCT03009474</DOCNO>
	<brief_summary>To compare pharmacokinetics safety single dose administration CJ-30060 Exforge® 5/160mg , Crestor 10mg healthy male volunteer .</brief_summary>
	<brief_title>Pharmacokinetics Study CJ-30060 After Single Dose Administration Health Male Volunteers</brief_title>
	<detailed_description>The purpose study compare pharmacokinetics safety single dose administration CJ-30060 Exforge® 5/160mg , Crestor 10mg healthy male volunteer .</detailed_description>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Amlodipine , Valsartan Drug Combination</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Healthy male age 20 45 year screen Subject 50kg BMI 18 kg/m2 29 kg/m2 ( inclusive ) Subject fully understand inform detailed description clinical trial , write informed consent voluntarily observe precaution . Subject medical history severe cardiovascular , respiratory , hepatobiliary , renal disease hematologic , gastrointestinal , endocrinological , immunologic , dermatosis neuropsychologic disease . Subject symptom , result acute disease within 28days first administration . Subject chronic persisting disease clinical significance . Subject fall criterion laboratory test . AST/ALT &gt; UNL ( upper normal limit ) x 2 Total bilirubin &gt; UNL x 1.5 In case renal failure creatine clearance le 50mL/min accord CockcroftGault CPK &gt; UNL x 2.5 Subject low blood pressure clinical significance screen test . ( systolic blood pressure le 90 mmHg diastolic blood pressure le 60 mmHg ) Subject positive reaction HBs Ag , antiHCV Ab , antiHIV Ab , VDRL test .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>